BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843-861. [PMID: 23537368 DOI: 10.1517/14656566.2013.782286] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Özbalcı GS, Yürüker SS, Tarım İA, Çınar H, Polat AK, Özbalcı AB, Karabulut K, Erzurumlu K. First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic. Ulus Cerrahi Derg 2014;30:133-7. [PMID: 25931914 DOI: 10.5152/UCD.2014.2678] [Reference Citation Analysis]
2 Ermis F, Tasci ES. Current Helicobacter pylori treatment in 2014. World J Methodol 2015; 5(2): 101-107 [PMID: 26140276 DOI: 10.5662/wjm.v5.i2.101] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
3 Muller N, Amiot A, Le Thuaut A, Bastuji-garin S, Deforges L, Delchier J. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clinics and Research in Hepatology and Gastroenterology 2016;40:517-24. [DOI: 10.1016/j.clinre.2015.12.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
4 Gao CP, Zhou Z, Wang JZ, Han SX, Li LP, Lu H. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis. J Dig Dis. 2016;17:811-819. [PMID: 27977071 DOI: 10.1111/1751-2980.12432] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
5 Zagari RM, Rabitti S, Eusebi LH, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest. 2018;48. [PMID: 29144559 DOI: 10.1111/eci.12857] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
6 Katelaris PH, Katelaris AL. A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia: Levofloxacin triple therapy for refractory H. pylori. Intern Med J 2017;47:761-6. [DOI: 10.1111/imj.13432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
7 Kahramanoğlu Aksoy E, Pirinçci Sapmaz F, Göktaş Z, Uzman M, Nazlıgül Y. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Med Princ Pract 2017;26:523-9. [PMID: 29131124 DOI: 10.1159/000484930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Burgos‐santamaría D, Mcnicholl AG, Gisbert JP. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients. GastroHep 2019;1:311-24. [DOI: 10.1002/ygh2.372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
9 Kanizaj TF, Kunac N. Helicobacter pylori: Future perspectives in therapy reflecting three decades of experience. World J Gastroenterol 2014; 20(3): 699-705 [PMID: 24574743 DOI: 10.3748/wjg.v20.i3.699] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
10 Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuño J, Barrio J, Huguet JM, Modollel I, Alcaide N, Lucendo A, Calvet X, Perona M, Gomez B, Gomez Rodriguez BJ, Varela P, Jimenez-Moreno M, Dominguez-Cajal M, Pozzati L, Burgos D, Bujanda L, Hinojosa J, Molina-Infante J, Di Maira T, Ferrer L, Fernández-Salazar L, Figuerola A, Tito L, de la Coba C, Gomez-Camarero J, Fernandez N, Caldas M, Garre A, Resina E, Puig I, O'Morain C, Megraud F, Gisbert JP. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter 2020;25:e12722. [PMID: 32656898 DOI: 10.1111/hel.12722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Reference Citation Analysis]
12 Singh SP, Ahuja V, Ghoshal UC, Makharia G, Dutta U, Zargar SA, Venkataraman J, Dutta AK, Mukhopadhyay AK, Singh A, Thapa BR, Vaiphei K, Sathiyasekaran M, Sahu MK, Rout N, Abraham P, Dalai PC, Rathi P, Sinha SK, Bhatia S, Patra S, Ghoshal U, Poddar U, Mouli VP, Kate V. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian J Gastroenterol 2021. [PMID: 34219211 DOI: 10.1007/s12664-021-01186-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial. BMC Gastroenterol. 2016;16:79. [PMID: 27460100 DOI: 10.1186/s12876-016-0490-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
14 Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020;25:E5084. [PMID: 33147814 DOI: 10.3390/molecules25215084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ji Y, Lu H. Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLoS One 2018;13:e0189888. [PMID: 29370199 DOI: 10.1371/journal.pone.0189888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
16 Heo J, Jeon SW, Jung JT, Kwon JG, Lee DW, Kim HS, Yang CH, Park JB, Park KS, Cho KB. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. J Gastroenterol Hepatol. 2015;30:1361-1366. [PMID: 25867608 DOI: 10.1111/jgh.12983] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
17 Mubeen B, Ansar AN, Rasool R, Ullah I, Imam SS, Alshehri S, Ghoneim MM, Alzarea SI, Nadeem MS, Kazmi I. Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics. Antibiotics (Basel) 2021;10:1473. [PMID: 34943685 DOI: 10.3390/antibiotics10121473] [Reference Citation Analysis]
18 Jung H, Kang SJ, Lee YC, Yang H, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. Korean J Helicobacter Up Gastrointest Res 2020;20:261-87. [DOI: 10.7704/kjhugr.2020.0045] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Alsohaibani F, Alquaiz M, Alkahtani K, Alashgar H, Peedikayil M, AlFadda A, Almadi M. Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia. Saudi J Gastroenterol 2020;26:84-8. [PMID: 32295933 DOI: 10.4103/sjg.SJG_626_19] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
20 Siddique O, Ovalle A, Siddique AS, Moss SF. Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance. The American Journal of Medicine 2018;131:473-9. [DOI: 10.1016/j.amjmed.2017.12.024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
21 Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
22 Kim J, Kim Y, Chung WC. Proton Pump Inhibitor Switching Strategy after Failure of Standard Triple Therapy for Helicobacter pylori Infection. Korean J Helicobacter Up Gastrointest Res 2020;20:146-52. [DOI: 10.7704/kjhugr.2019.0036] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Haider RB, Brennan DE, Omorogbe J, Holleran G, Hall B, O'Morain C, Breslin N, O'Connor HJ, Smith SM, McNamara D. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. Eur J Gastroenterol Hepatol. 2015;27:1265-1269. [PMID: 26287955 DOI: 10.1097/meg.0000000000000457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
24 Smith S, Boyle B, Brennan D, Buckley M, Crotty P, Doyle M, Farrell R, Hussey M, Kevans D, Malfertheiner P. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol. 2017;29:552-559. [PMID: 28350745 DOI: 10.1097/meg.0000000000000822] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
25 Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51-69.e14. [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006] [Cited by in Crossref: 362] [Cited by in F6Publishing: 311] [Article Influence: 60.3] [Reference Citation Analysis]
26 Molina-Infante J, Shiotani A. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterol Clin North Am 2015;44:519-35. [PMID: 26314666 DOI: 10.1016/j.gtc.2015.05.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
27 Hsu PI, Tsai FW, Kao SS, Hsu WH, Cheng JS, Peng NJ, Tsai KW, Hu HM, Wang YK, Chuah SK, Chen A, Wu DC. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. Am J Gastroenterol. 2017;112:1374-1381. [PMID: 28719592 DOI: 10.1038/ajg.2017.195] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
28 Lim HC, Lee YJ, An B, Lee SW, Lee YC, Moon BS. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19:455-461. [PMID: 25231089 DOI: 10.1111/hel.12147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
29 Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
30 McNicholl AG, Gisbert JP. In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal. Evid Based Med 2016;21:144. [PMID: 27388800 DOI: 10.1136/ebmed-2016-110458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 O’Connor A, Vaira D, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2014. Helicobacter. 2014;19 Suppl 1:38-45. [PMID: 25167944 DOI: 10.1111/hel.12163] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
32 Smith SM, Haider RB, O'Connor H, McNamara D, O'Morain C. Practical treatment of Helicobacter pylori: a balanced view in changing times. Eur J Gastroenterol Hepatol. 2014;26:819-825. [PMID: 24892516 DOI: 10.1097/meg.0000000000000130] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
33 Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014; 20(6): 1517-1528 [PMID: 24587627 DOI: 10.3748/wjg.v20.i6.1517] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
34 Narayana JL, Huang HN, Wu CJ, Chen JY. Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model. Oncotarget 2015;6:12936-54. [PMID: 26002554 DOI: 10.18632/oncotarget.4101] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
35 Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L, Cosme A, Gisbert JL, Fernández-Bermejo M, Marcos S, Marín AC, McNicholl AG. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci 2015;60:458-64. [PMID: 25236423 DOI: 10.1007/s10620-014-3365-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
36 Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34:59-67. [PMID: 30169908 DOI: 10.1111/jgh.14462] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
37 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M;  Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168-195. [PMID: 33468712 DOI: 10.5009/gnl20288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
38 Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212-239. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 515] [Cited by in F6Publishing: 415] [Article Influence: 103.0] [Reference Citation Analysis]
39 Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2016;39:697-721. [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
40 Marin AC, Nyssen OP, Mcnicholl AG, Gisbert JP. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs 2017;77:765-76. [DOI: 10.1007/s40265-017-0730-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
41 Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC; Taiwan Acid-related Disease, Microbiota (TARD-M) Consortium. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter 2021;:e12840. [PMID: 34390083 DOI: 10.1111/hel.12840] [Reference Citation Analysis]
42 Muñoz N, Sánchez-Delgado J, Baylina M, López-Góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterol Hepatol 2018;41:654-62. [PMID: 30180998 DOI: 10.1016/j.gastrohep.2018.06.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Yang H, Jung H, Kang SJ, Lee YC, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Salvage Regimens after Failure of Previous Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. Korean J Helicobacter Up Gastrointest Res 2021;21:59-71. [DOI: 10.7704/kjhugr.2020.0053] [Reference Citation Analysis]
44 Gisbert JP, Molina-Infante J. Current treatment of Helicobacter pylori infection. Med Clin (Barc) 2017;148:20-2. [PMID: 27916266 DOI: 10.1016/j.medcli.2016.10.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 992] [Article Influence: 194.3] [Reference Citation Analysis]
46 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
47 Chew CA, Lye TF, Ang D, Ang TL. The diagnosis and management of H. pylori infection in Singapore. Singapore Med J 2017;58:234-40. [PMID: 28536725 DOI: 10.11622/smedj.2017037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Nyssen OP, Pérez-Aisa Á, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Brglez Jurecic N, Huguet JM, Alcaide N, Voynovan I, María Botargues Bote J, Modolell I, Pérez Lasala J, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Marcos Pinto R, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, Boyanova L, Shvets O, Venerito M, Bytzer P, Goldis A, Simsek I, Lamy V, Przytulski K, Kunovský L, Capelle L, Milosavljevic T, Caldas M, Garre A, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg). Helicobacter 2020;25:e12686. [PMID: 32173974 DOI: 10.1111/hel.12686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]